Abstract: A method of training a prediction tool to generate at least one synthetic full-contrast image from zero-contrast and low-contrast images of a subject may involve receiving a training set a set of images of a set of subjects, the images of each subject comprising a full-contrast image, a low-contrast image, a first zero-contrast image acquired prior to the acquisition of the full-contrast image, and a second zero-contrast image acquired prior to the acquisition of the low-contrast image. An artificial neural network may be trained with the training set by applying the first and second zero-contrast images from the set of images and the low-contrast images from the set of images as input to the artificial neural network and using a cost function to compare the output of the artificial neural network with the full-contrast images from the set of images to train parameters of the artificial neural network using backpropagation.

Abstract: The present invention relates to a composition comprising a) recombinant exosporium-producing Bacillus cells that express a fusion protein comprising: (i) at least one plant growth stimulating protein or peptide and (ii) a targeting sequence that localizes the fusion protein to the exosporium of the Bacillus cells; and b) at least one particular fungicide disclosed herein in a synergistically effective amount. Furthermore, the present invention relates to the use of this composition as well as a method for enhancing plant growth, promoting plant health, and/or reducing overall damage of plants and plant parts.

Abstract: The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

Abstract: The present invention relates to a novel process for preparing substituted cyclohexane amino acid esters and spiroketal-substituted cyclic keto-enols, and to novel intermediates or starting compounds that are passed through or used in the process according to the invention.

Abstract: The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

Abstract: The present invention provides dihydropyridazinone compounds of general formula (I) in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.

Abstract: The present invention relates to a new class of compounds of general formula (I), the Gd3+ chelate complexes thereof, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.

Abstract: The present invention relates to the technical field of machine learning. Subject matter of the present invention is a novel approach for training a neural network and the use of this approach for the processing of (medical) images.

Abstract: A syringe includes a barrel having a proximal end, a distal end, and a sidewall extending substantially circumferentially between the proximal end and the distal end along a longitudinal axis. The barrel is formed from an injection molding process including aligning a mold die defining an internal shape of the barrel in a molding cavity defining an external shape of the barrel, the molding cavity defined by first and second mold sections. Each mold section includes at least one gate adapted to control the flow of a molding material into the molding cavity. The gates of each mold section are opened to permit the first and second melt streams of molding material to fill the molding cavity surrounding the mold die, where the molding material takes the shape of the molding cavity.

Abstract: A plunger for use with a syringe includes a plunger body defining a central longitudinal axis and having a proximal end, a distal end, and a circumferential sidewall connecting the proximal end and the distal end. The plunger further includes at least one retaining member associated with and extending proximally from the plunger body. The at least one retaining member has a first end connected to the plunger body, a second end proximal to the first end and radially and resiliently deflectable relative to the first end, and at least one catch on the second end. A fluid injector system includes a piston having a plunger engagement mechanism configured for interacting with the at least one retaining element of the plunger to releasably engage the plunger for reciprocally driving the plunger within a barrel of the syringe.

Abstract: Described are systems and methods for assessing a likelihood of chronic thromboembolic pulmonary hypertension (CTEPH) within a subject patient based upon an analysis of characteristics indicative of chronic thromboembolic pulmonary hypertension within an imaging study of the subject patient. The systems and methods can identify characteristics of one or more anatomical structures within a cardiac region of the subject patient indicative of CTEPH, characteristics of a pulmonary vasculature of the subject patient indicative of CTEPH, and characteristics of a chronic abnormality in a lung of the subject patient indicative of CTEPH. The systems and methods can assess these characteristics to compute the likelihood of CTEPH within the subject patient.

Abstract: The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.

Abstract: A fluid injector system has a controller for operably controlling the injection of contrast and/or saline into a patient. The controller allows a user to program a diagnostic injection procedure having one or more phases according to which the contrast and/or saline will be injected into the patient so as to effect enhancement of a region thereof during an imaging procedure. It further allows the user to program a test injection procedure to be performed prior to the diagnostic injection procedure. The test injection procedure is implementable as: (a) a variable single phase test injection in which the rate at which the saline is to be delivered is selectable prior to and may be varied during performance thereof; and/or (b) a multi-phase test injection in which the rate at which the saline is to be delivered is selectable for each phase of the multi-phase test injection prior to performance thereof.

Abstract: The present invention relates to Map4K1 inhibitors of formula (I) (I), wherein A, E, G, Q, R1, R2 and R4 have the same meaning as defined in the description, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients.

Abstract: A method is provided for authenticating, and establishing and tracking eligibility of a patient to purchase an over-the-counter (OTC) drug from a retailer, the patient using a client device or terminal and the retailer having a server. The server is configured to redirect the client device or terminal to a backend platform to authenticate the patient, access a storage to search for any information that indicates the patient is ineligible to purchase the OTC drug; and without any information that indicates the patient is ineligible, administer a questionnaire to the patient to assess the eligibility for the OTC drug. And the backend platform redirects the client device or terminal back to the server to complete the online sale of the OTC drug to the patient when the patient is eligible, or cancel the online sale of the OTC drug to the patient when the patient is ineligible.

Abstract: The present invention relates to an inserter for an intrauterine system comprising a handle (3), and an insertion tube (6) having a first end and a second end, and being arranged in connection with the handle. The inserter is characterized in that the first end of the insertion tube (6) comprises at least one frame slot for receiving a frame of the intrauterine system. The invention also relates to a kit comprising an inserter according to the present invention and an intrauterine system, wherein the intrauterine system (1) comprises a therapeutic component (1b) and a continuous, closed frame (1a), the therapeutic component (1b) being connected to the frame (1a) at least one point, and therapeutic component (1b) of the intrauterine system (1) is at least mainly arranged inside the first end of the insertion tube (6) and the frame (1a) of the intrauterine system (1) is at least mainly arranged outside the first end of the insertion tube (6).

Abstract: The present application relates to substituted indazoles, to the use thereof alone or in combinations for treatment and/or prophylaxis of autoimmune disorders, and to the use thereof for production of medicaments for treatment and/or prophylaxis of autoimmune disorders, especially for treatment and/or prophylaxis of arthritides (especially psoriatic arthritis, rheumatoid arthritis, Bekhterev's disease, reactive arthritis, systematic juvenile idiopathic arthritis), systematic lupus erythematosus, multiple sclerosis, psoriasis, atopic dermatitis, allergic eczema and chronic-inflammatory bowel disorders (especially Crohn's disease and ulcerative colitis).